Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer

Nonparametric Estimation from Incomplete Observations

1992 • 45,923 citations

Nonparametric Estimation from Incomplete Observations

1958 • 37,219 citations

Regression Models and Life-Tables

1972 • 27,145 citations

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2004 • 11,185 citations

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

2004 • 4,992 citations

Optimal two-stage designs for phase II clinical trials

1989 • 3,494 citations

Rising Incidence of Hepatocellular Carcinoma in the United States

1999 • 2,875 citations

The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy

1999 • 840 citations

Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection

1994 • 380 citations

Clinical trials in primary hepatocellular carcinoma: current status and future directions

1988 • 223 citations

Anticancer drug targets: growth factors and growth factor signaling

2000 • 149 citations

Confidence Intervals for a Binomial Parameter Based on Multistage Tests

1987 • 141 citations

Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein

2001 • 132 citations

Adriamycin treatment for hepatocellular carcinoma experience with 109 patients

1985 • 118 citations

Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results.

1984 • 109 citations

Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin

2004 • 95 citations

Nodules of less-differentiated tumor within or adjacent to hepatocellular carcinoma: Relative expression of transforming growth factor-α and its receptor in the different areas of tumor

1995 • 75 citations

Adriamycin therapy in American patients with hepatocellular carcinoma.

1977 • 57 citations

Hypomethylation of c-myc and epidermal growth factor receptor genes in human hepatocellular carcinoma and fetal liver.

1985 • 53 citations

Concomitant and isolated expression of TGF‐alpha and EGF‐R in human hepatoma cells supports the hypothesis of autocrine, paracrine, and endocrine growth of human hepatoma

1995 • 50 citations

Systemic and regional treatment of primary carcinoma of the liver

1977 • 32 citations

Inhibition of growth of primary human tumour cell cultures by a 4-anilinoquinazoline inhibitor of the epidermal growth factor receptor family of tyrosine kinases

1998 • 24 citations

Phase II Trial of erlotinib (OSI-774) in patients with hepatocellular or biliary cancer

2004 • 23 citations

Effects of epidermal growth factor on growth control and signal transduction pathways in different human hepatoma cell lines.

1993 • 21 citations

[Immunohistochemical studies on epidermal growth factor receptor in hepatocellular carcinoma].

1991 • 13 citations

Phase II Trial of erlotinib (OSI-774) in patients with hepatocellular or biliary cancer

2004 • 12 citations

Introduction

1988 • 1 citations

Deleted Work

1955 • 0 citations